trifluoperazine has been researched along with Disease Models, Animal in 23 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion." | 7.96 | The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. ( Alli, C; Bhat, K; Cheng, F; Cloughesy, TF; Damoiseaux, R; Duhachek-Muggy, S; He, L; Kornblum, HI; Liau, LM; Medina, P; Nghiemphu, PL; Pajonk, F; Pellegrini, M; Saki, M; Vlashi, E; Yu, G; Zemke, NR, 2020) |
| "Stroke is the second leading cause of death and the third leading cause of disability globally." | 5.62 | The effects of trifluoperazine on brain edema, aquaporin-4 expression and metabolic markers during the acute phase of stroke using photothrombotic mouse model. ( Herlo, R; Hou, H; Kelly, ME; Meher, V; Peeling, L; Pushie, MJ; Salman, MM; Sylvain, NJ, 2021) |
| " The in vivo therapeutic potential of TFP was tested in two preclinical models with established PAH, namely the monocrotaline and sugen/hypoxia-induced rat models." | 4.02 | Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension. ( Awada, C; Bonnet, S; Boucherat, O; Bourgeois, A; Breuils-Bonnet, S; Grobs, Y; Lemay, SE; Nadeau, V; Orcholski, M; Paulin, R; Provencher, S; Romanet, C; Shimauchi, K; Toro, V; Tremblay, E, 2021) |
| " We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion." | 3.96 | The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. ( Alli, C; Bhat, K; Cheng, F; Cloughesy, TF; Damoiseaux, R; Duhachek-Muggy, S; He, L; Kornblum, HI; Liau, LM; Medina, P; Nghiemphu, PL; Pajonk, F; Pellegrini, M; Saki, M; Vlashi, E; Yu, G; Zemke, NR, 2020) |
| " A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y." | 3.83 | New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. ( Andersson, JA; Chauhan, S; Chopra, AK; Dann, SM; Fitts, EC; Kirtley, ML; Motin, VL; Peniche, AG; Ponnusamy, D; Rosenzweig, JA; Sha, J, 2016) |
| "Stroke is the second leading cause of death and the third leading cause of disability globally." | 1.62 | The effects of trifluoperazine on brain edema, aquaporin-4 expression and metabolic markers during the acute phase of stroke using photothrombotic mouse model. ( Herlo, R; Hou, H; Kelly, ME; Meher, V; Peeling, L; Pushie, MJ; Salman, MM; Sylvain, NJ, 2021) |
| "Trifluoperazine was less effective against acetylcholine-induced tone in sensitized, as compared to untreated, trachea." | 1.29 | Effects of two Ca2+ modulators in normal and albumin-sensitized guinea-pig trachea. ( De Jonckheere, S; McCaig, D, 1993) |
| " An experimental study of the long-term administrations of haloperidol revealed the formation of adaptation to the drug which can be overcome by a zigzag-like sharp elevation of the dosage followed by rapid reduction to the baseline level." | 1.27 | [Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)]. ( Allikmets, LKh; Avrutskiĭ, GIa; Beliakov, AV; Neduva, AA; Zharkovskiĭ, AM, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ding, Q | 1 |
| Sethna, F | 1 |
| Wu, XT | 1 |
| Miao, Z | 1 |
| Chen, P | 1 |
| Zhang, Y | 2 |
| Xiao, H | 1 |
| Feng, W | 1 |
| Feng, Y | 1 |
| Li, X | 1 |
| Wang, H | 1 |
| Bhat, K | 1 |
| Saki, M | 1 |
| Vlashi, E | 1 |
| Cheng, F | 1 |
| Duhachek-Muggy, S | 1 |
| Alli, C | 1 |
| Yu, G | 1 |
| Medina, P | 1 |
| He, L | 1 |
| Damoiseaux, R | 1 |
| Pellegrini, M | 1 |
| Zemke, NR | 1 |
| Nghiemphu, PL | 1 |
| Cloughesy, TF | 1 |
| Liau, LM | 1 |
| Kornblum, HI | 1 |
| Pajonk, F | 1 |
| Kiani, A | 1 |
| Nik, SH | 1 |
| Khodadoost, A | 1 |
| Salimi, A | 1 |
| Pourahmad, J | 1 |
| Sylvain, NJ | 1 |
| Salman, MM | 1 |
| Pushie, MJ | 1 |
| Hou, H | 1 |
| Meher, V | 1 |
| Herlo, R | 1 |
| Peeling, L | 1 |
| Kelly, ME | 1 |
| Grobs, Y | 1 |
| Awada, C | 1 |
| Lemay, SE | 1 |
| Romanet, C | 1 |
| Bourgeois, A | 1 |
| Toro, V | 1 |
| Nadeau, V | 1 |
| Shimauchi, K | 1 |
| Orcholski, M | 1 |
| Breuils-Bonnet, S | 1 |
| Tremblay, E | 1 |
| Provencher, S | 1 |
| Paulin, R | 1 |
| Boucherat, O | 1 |
| Bonnet, S | 1 |
| Khaledi, E | 1 |
| Noori, T | 1 |
| Mohammadi-Farani, A | 1 |
| Sureda, A | 1 |
| Dehpour, AR | 1 |
| Yousefi-Manesh, H | 1 |
| Sobarzo-Sanchez, E | 1 |
| Shirooie, S | 1 |
| Nguyen, DT | 1 |
| Olzomer, EM | 1 |
| Poon, GP | 1 |
| Cole, NJ | 1 |
| Puvanendran, A | 1 |
| Phillips, BR | 1 |
| Hesselson, D | 1 |
| Andersson, JA | 1 |
| Fitts, EC | 1 |
| Kirtley, ML | 1 |
| Ponnusamy, D | 1 |
| Peniche, AG | 1 |
| Dann, SM | 1 |
| Motin, VL | 1 |
| Chauhan, S | 1 |
| Rosenzweig, JA | 1 |
| Sha, J | 1 |
| Chopra, AK | 1 |
| Kang, S | 1 |
| Hong, J | 1 |
| Lee, JM | 1 |
| Moon, HE | 1 |
| Jeon, B | 1 |
| Choi, J | 1 |
| Yoon, NA | 1 |
| Paek, SH | 1 |
| Roh, EJ | 1 |
| Lee, CJ | 1 |
| Kang, SS | 1 |
| Akel, I | 1 |
| Demirkiran, G | 1 |
| Alanay, A | 1 |
| Karahan, S | 1 |
| Marcucio, R | 1 |
| Acaroglu, E | 1 |
| Yeh, CT | 1 |
| Wu, AT | 1 |
| Chang, PM | 1 |
| Chen, KY | 1 |
| Yang, CN | 1 |
| Yang, SC | 1 |
| Ho, CC | 1 |
| Chen, CC | 1 |
| Kuo, YL | 1 |
| Lee, PY | 1 |
| Liu, YW | 1 |
| Yen, CC | 1 |
| Hsiao, M | 1 |
| Lu, PJ | 1 |
| Lai, JM | 1 |
| Wang, LS | 1 |
| Wu, CH | 1 |
| Chiou, JF | 1 |
| Yang, PC | 1 |
| Huang, CY | 1 |
| Sato, T | 1 |
| Morishima, Y | 1 |
| Shirasaki, Y | 1 |
| Goswick, SM | 1 |
| Brenner, GM | 1 |
| Avrutskiĭ, GIa | 1 |
| Allikmets, LKh | 1 |
| Neduva, AA | 1 |
| Zharkovskiĭ, AM | 1 |
| Beliakov, AV | 1 |
| McCaig, D | 1 |
| De Jonckheere, S | 1 |
| Kadar, T | 1 |
| Fishbeine, E | 1 |
| Meshulam, Y | 1 |
| Sahar, R | 1 |
| Chapman, S | 1 |
| Liani, H | 1 |
| Barness, I | 1 |
| Amir, A | 1 |
| Dill, RE | 1 |
| Dorris, RL | 1 |
| Phillips-Thonnard, I | 1 |
| Mitrová, E | 1 |
| Mayer, V | 1 |
| Clow, A | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Viluksela, M | 1 |
| Silver, PJ | 1 |
| Monteforte, PB | 1 |
23 other studies available for trifluoperazine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Drug Repositioning; Fragile X Mental Retardation | 2020 |
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
Topics: Animals; beta Catenin; Brain Neoplasms; Disease Models, Animal; Dopamine Antagonists; Gene Expressio | 2020 |
Trifluoperazine an Antipsychotic Drug and Inhibitor of Mitochondrial Permeability Transition Protects Cytarabine and Ifosfamide-Induced Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Brain; Cells, Cultured; Cytarabine; Disease Models, Animal; Humans; | 2020 |
The effects of trifluoperazine on brain edema, aquaporin-4 expression and metabolic markers during the acute phase of stroke using photothrombotic mouse model.
Topics: Animals; Aquaporin 4; Biomarkers; Brain; Disease Models, Animal; Glycogen; Male; Mice; Mice, Inbred | 2021 |
Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.
Topics: Animals; Antipsychotic Agents; Cardiovascular Agents; Cell Proliferation; Disease Models, Animal; Dr | 2021 |
Trifluoperazine reduces cuprizone-induced demyelination via targeting Nrf2 and IKB in mice.
Topics: Animals; Cuprizone; Disease Models, Animal; Humans; I-kappa B Proteins; Male; Mice; Multiple Scleros | 2021 |
Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Behavior, Animal; C | 2017 |
New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
Topics: Amoxapine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Clostridioides difficile | 2016 |
Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R.
Topics: Animals; Antineoplastic Agents; Calcium; Calmodulin; Cell Line, Tumor; Cell Movement; Cell Survival; | 2017 |
The effect of calmodulin antagonists on scoliosis: bipedal C57BL/6 mice model.
Topics: Amputation, Surgical; Animals; Bone Density Conservation Agents; Calmodulin; Disease Models, Animal; | 2009 |
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Topics: Animals; Antipsychotic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diseas | 2012 |
3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, reduces brain edema through the inhibition of enhanced blood-brain barrier perme
Topics: Animals; Blood-Brain Barrier; Brain Edema; Calmodulin; Cell Membrane Permeability; Disease Models, A | 2003 |
Activities of therapeutic agents against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis.
Topics: Acetamides; Adolescent; Amebiasis; Amebicides; Amphotericin B; Animals; Central Nervous System Proto | 2003 |
[Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)].
Topics: Adult; Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Drug | 1984 |
Effects of two Ca2+ modulators in normal and albumin-sensitized guinea-pig trachea.
Topics: Acetylcholine; Albumins; Animals; Asthma; Calcium; Disease Models, Animal; Guinea Pigs; Immunization | 1993 |
Treatment of skin injuries induced by sulfur mustard with calmodulin antagonists, using the pig model.
Topics: Administration, Topical; Anesthetics, Local; Animals; Blister; Calmodulin; Dermatologic Agents; Dise | 2000 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, | 1976 |
Phenothiazine-induced alterations of immune response in experimental tick-borne encephalitis: morphological model analysis of events.
Topics: Animals; Antibody Formation; BCG Vaccine; Brain; Disease Models, Animal; Encephalitis, Tick-Borne; E | 1976 |
An experimental model of tardive dyskinesias.
Topics: Animals; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Male; Motor Activity; Rats | 1978 |
Characteristics and modulation of dithranol (anthralin)-induced skin irritation in the mouse ear model.
Topics: Administration, Topical; Adrenal Cortex Hormones; Animals; Anthralin; Anti-Inflammatory Agents, Non- | 1991 |
Differential effects of pharmacological modulators of cardiac myofibrillar ATPase activity in normal and myopathic (BIO 14.6) hamsters.
Topics: Adenosine Triphosphatases; Animals; Anti-Arrhythmia Agents; Bepridil; Calcium; Calcium Channel Block | 1988 |